DNA interstrand cross-link repair: Understanding role of Fanconi anemia pathway and therapeutic implications

European Journal of Haematology

Volumn 91, Issue 5, 2013, Pages 381-393

  Shukla, Pallavi ^a   Solanki, Avani ^a   Ghosh, Kanjaksha ^a   Vundinti, Babu Rao ^a  

^a NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

Cancer; Chemotherapy; Fanconi anemia; Interstrand cross links

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLINE; CYCLOPHOSPHAMIDE; DACARBAZINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP E PROTEIN; FANCONI ANEMIA GROUP F PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; FANCONI ANEMIA PROTEIN; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOXSALEN; MITOMYCIN; OXALIPLATIN; PROCARBAZINE; SATRAPLATIN; SEMUSTINE; STREPTOZOCIN; THIOTEPA; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ALOPECIA; AMENORRHEA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; AZOOSPERMIA; BIOTRANSFORMATION; BLADDER CANCER; BLADDER CARCINOMA; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BONE PAIN; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CENTRAL NERVOUS SYSTEM DEPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COVALENT BOND; DIARRHEA; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DNA STRAND; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG STRUCTURE; ESOPHAGUS CANCER; EXCISION REPAIR; FANCONI ANEMIA; FIBROSIS; FLU LIKE SYNDROME; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TOXICITY; GENOTOXICITY; HAIR LOSS; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC CYSTITIS; HODGKIN DISEASE; HOMOLOGOUS RECOMBINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; IMPOTENCE; INFECTION; INFERTILITY; INTERSTITIAL PNEUMONIA; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY INJURY; LEUKEMIA; LEUKOPENIA; LIVER NECROSIS; LIVER TOXICITY; LUNG CANCER; LUNG FIBROSIS; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MELANOMA METASTASIS; MISMATCH REPAIR; MOUTH ULCER; MULTIPLE MYELOMA; MYELOMA; NAIL; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OTOTOXICITY; OVARY CANCER; PANCREAS ISLET CELL CARCINOMA; PANCREAS METASTASIS; PANCYTOPENIA; PAPILLARY CARCINOMA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SECOND CANCER; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN; SOFT TISSUE SARCOMA; STOMATITIS; TACHYCARDIA; TESTIS CANCER; THROMBOCYTOPENIA; TOXIC HEPATITIS; ULTRAVIOLET A RADIATION; URINARY EXCRETION; VOMITING;

CANCER; CHEMOTHERAPY; FANCONI ANEMIA; INTERSTRAND CROSS-LINKS;

AZIRIDINES; CELL CYCLE; CROSS-LINKING REAGENTS; DNA DAMAGE; DNA REPAIR; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; GENE EXPRESSION REGULATION; HUMANS; NITROGEN MUSTARD COMPOUNDS; PLATINUM COMPOUNDS; SIGNAL TRANSDUCTION;

EID: 84885939253     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12169     Document Type: Review

References (106)

1. Vasquez KM, Legerski RJ. DNA interstrand crosslinks: repair, cell signaling, and therapeutic implications. Environ Mol Mutagen 2010;51:491-2.
2. Guainazzi A, Scharer OD. Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy. Cell Mol Life Sci 2010;67:3683-97.
3. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011;11:46780.
4. Auerbach AD, Buchwald M, Joenje H. Fanconi anemia, In: Scriver CR, Sly WS, Childs B, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. Vol 1, 8th edn. New York: McGraw-Hill; 2001:753-68.
5. D'Andrea AD, Grompe M. Molecular biology of Fanconi anemia: implications for diagnosis and therapy. Blood 1997;90:1725-36.
6. Svahn J, Dufour C. Fanconi anemia -learning from children. Pediatr Rep 2011;3:e8.
7. Tulpule A, Lensch MW, Miller JD, et al. Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood 2010;115:3453-62.
8. Dhillon VS, Shahid M, Husain SA. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer 2004;3:33.
9. Marsit CJ, Liu M, Nelson HH, et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004;23:1000-4.
10. Narayan G, Arias-Pulido H, Nandula SV, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 2004;64:2994-7.
11. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
12. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63:2585-8.
13. O'Brien PJ, Siraki AG, Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms and possible effects on human health. Crit Rev Toxicol 2005;35:609-62.
14. Nagayoshi H, Mastumoto A, Nishi R, Kawamoto T, Ichiba M, Matsuda T. Increased formation of gastric N2-ethylidene-29-deoxyguanosine DNA adducts in aldehyde dehydrogenase-2 knockout mice treated with ethanol. Mutat Res 2009;673:74-7.
15. Matsuda T, Matsumoto A, Uchida M, et al. Increased formation of hepatic N2-ethylidene-29-deoxyguanosine DNA adducts in aldehyde dehydrogenase-2 knockout mice treated with ethanol. Carcinogenesis 2007;28:2363-6.
16. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007;7:599-612.
17. Langevin F, Crossan GP, Rosado IV, et al. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011;475:53-8.
18. Garaycoechea JI, Crossan GP, Langevin F, et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 2012;489:571-5.
19. Ceccaldi R, Parmar K, Mouly E, et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012;11:36-49.
20. Svendsen JM, Smogorzewska A, Sowa ME, et al. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 2009;138:63-77.
21. Green AM, Kupfer GM. Fanconi anemia. Hematol Oncol Clin North Am 2009;23:193-214.
22. Meetei AR, Medhurst AL, Ling C, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet 2005;37:958-63.
23. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003;35:165-70.
24. Smogorzewska A, Desetty R, Saito TT, et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell 2010;39:36-47.
25. McCulloch SD, Kunkel TA. The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res 2008;18:148-61.
26. Andersen PL, Xu F, Xiao W. Eukaryotic DNA damage tolerance and translesion synthesis through covalent modifications of PCNA. Cell Res 2008;18:162-73.
27. Prakash S, Johnson RE, Prakash L. Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. Annu Rev Biochem 2005;74:317-53.
28. Polanowska J, Martin JS, Garcia-Muse T, Petalcorin MI, Boulton SJ. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites. EMBO J 2006;25:2178-88.
29. Thorslund T, McIlwraith MJ, Compton SA, Lekomtsev S, Petronczki M, Griffith JD, West SC. The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nat Struct Mol Biol 2010;17:1263-5.
30. Wu L, Hickson ID. The Bloom's syndrome helicase suppresses crossing over during homologous recombination. Nature 2003;426:870-4.
31. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 1993;72:131-42.
32. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003;4:712-20.
33. Hlavin EM, Smeaton MB, Miller PS. Initiation of DNA interstrand cross-link repair in mammalian cells. Environ Mol Mutagen 2010;51:604-24.
34. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross) linked to DNA repair. Cell 2005;123:1191-8.
35. Thompson LH, Hinz JM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res 2009;668:54-72.
36. Bhagwat N, Olsen AL, Wang AT, et al. XPF-ERCC1 participates in the Fanconi anemia pathway of crosslink repair. Mol Cell Biol 2009;29:6427-37.
37. Smeaton MB, Hlavin EM, McGregor Mason T, et al. Distortion-dependent unhooking of interstrand cross-links in mammalian cell extracts. Biochemistry 2008;47:9920-30.
38. Smeaton MB, Hlavin EM, Noronha AM, Murphy SP, Wilds CJ, Miller PS. Effect of cross-link structure on DNA interstrand cross-link repair synthesis. Chem Res Toxicol 2009;22:1285-97.
39. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000;59:9-17; discussion 37-8.
40. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J. The Anticancer Drugs. New York: Oxford University Press, 1994.
41. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490-518.
42. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986;8:368-79.
43. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007;334:115-24.
44. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197:165-7.
45. Treskes M, van der Vijgh WJ. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother Pharmacol 1993;33:93-106.
46. Smith IE, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Calvert AH, Yarnold J, Glees JP, Baker J, Ford HT. Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 1985;69:43-6.
47. Doshi G, Sonpavde G, Sternberg CN. Clinical and pharmacokinetic evaluation of satraplatin. Expert Opin Drug Metab Toxicol 2012;8:103-11.
48. Yaman E, Uner A, Er O, et al. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. Med Oncol 2007;24:431-5.
49. Eckardt JR, Bentsion DL, Lipatov ON, Polyakov IS, Mackintosh FR, Karlin DA, Baker GS, Breitz HB. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009;27:2046-51.
50. Zamlauski-Tucker MJ, Morris ME, Springate JE. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 1994;129:170-5.
51. Catovsky D, Else M, Richards S. Chlorambucil-still not bad: a reappraisal. Clin Lymphoma Myeloma Leuk 2011;11:S2-6.
52. Evers B, Schut E, van der Burg E, et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010;16:99-108. Epub 2009 Dec 15.
53. McGuire WP 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003;89:S3-8.
54. Agnelli G, de Cunto M, Gresele P, del Favero A. Early onset life-threatening myelosuppression after low dose of intravesical thiotepa. Postgrad Med J 1982;58:380-1.
55. Binet JL. Treatment of chronic lymphocytic leukaemia. French Co-operative Group on CLL. Baillieres Clin Haematol 1993;6:867-78.
56. Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003;17:841-8.
57. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71.
58. ® in streptozotocin induced diabetes mellitus in rats. Bang J Vet Med 2010;8:75-80.
59. Weiss RB. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 1982;3:427-35.
60. Wilson GL, Leiter EH. Streptozotocin interactions with pancreatic β cells and the induction of insulin-dependent diabetes. Curr Topics Micro Immuno 1990;156:27-54.
61. Bolzan AD, Bianchi MS. Genotoxicity of Streptozotocin. Mutat Res 2002;512:121-34.
62. Sheweita SA. Drug-metabolizing enzymes: mechanisms and functions. Curr Drug Metab 2000;1:107-32.
63. Spiro T, Liu L, Gerson S. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. Forum (Genova) 2000;10:274-85.
64. Case DC Jr, Young CW, Lee BJ 3rd. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV). Cancer 1977;39:1382-6.
65. Bonadonna G, Valagussa P, Santoro A, Viviani S, Bonfante V, Banfi A. Hodgkin's disease: the Milan Cancer Institute experience with MOPP and ABVD. Recent Results Cancer Res 1989;117:169-74.
66. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990;18:321-4.
67. Verly WG. Monofunctional alkylating agents and apurinic sites in DNA. Biochem Pharmacol 1974;23:3.
68. Verly WG, Paquette Y. An endonuclease for depurinated DNA in Escherichia coli B. Can J Biochem 1972;50:217-24.
69. Szybalski W, Iyer VN. Crosslinking of DNA by enzymatically or chemically activated mitomycins and porfiromycins, bifunctionally "alkylating" antibiotics. Fed Proc 1964;23:946-57.
70. Pritsos CA, Sartorelli AC. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res 1986;46:3528-32.
71. Durse L, Rajagopalan S, Eliot HM, Covey JM, et al. DNA interstrand cross-link and free radical formation in a human multidrug resistant cell line from mitomycin C and its analogues. Cancer Res 1990;50:648-52.
72. Clarke AA, Philpott NJ, Gordon-Smith EC, et al. The sensitivity of Fanconi anaemia group C cells to apoptosis induced by mitomycin C is due to oxygen radical generation, not DNA crosslinking. Br J Haematol 1997;96:240-7.
73. Penketh PG, Hodnick WF, Belcourt MF, et al. Inhibition of DNA crosslinking by mitomycin C by peroxidase-mediated oxidation of mitomycin C hydroquinone. J Biol Chem 2001;276:34445-52.
74. Pagano G, Talamanca AA, Castello G, et al. Oxidative stress in Fanconi anemia: from cells and molecules towards prospects in clinical managements. Biol Chem 2012;393:11-21.
75. Joenje H, Oostra AB. Clastogenicity of cyclophosphamide in Fanconi's anemia lymphocytes without exogenous metabolic activation. Cancer Genet Cytogenet 1986;22:339-45.
76. Barouki R, Morel Y. Repression of cytochrome P450 1A1 gene expression by oxidative stress: mechanisms and biological implications. Biochem Pharmacol 2001;61:511-6.
77. Kruyt FA, Hoshino T, Liu JM, et al. Abnormal microsomal detoxification implicated in Fanconi anemia group C by interaction of the FAC protein with NADPH cytochrome P450 reductase. Blood 1998;92:3050-6.
78. Cumming RC, Lightfoot J, Beard K, et al. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med 2001;7:814-20.
79. Futaki M, Igarashi T, Watanabe S. The FANCG Fanconi anemia protein interacts with CYP2E1: possible role in protection against oxidative DNA damage. Carcinogenesis 2002;23:67-72.
80. Vlachodimitropoulos D, Norppa H, Autio K, et al. GSTT1-dependent induction of centromere negative and -positive micronuclei by 1, 2:3, 4-diepoxybutane in cultured human lymphocytes. Mutagenesis 1997;12:397-403.
81. Boogaard PJ, Bond JA. The role of hydrolysis in the detoxification of 1, 2:3, 4-diepoxybutane by human, rat, and mouse liver and lung in vitro. Toxicol Appl Pharmacol 1996;141:617-27.
82. Spanò M, Cordelli E, Leter G, et al. Diepoxybutane cytotoxicity on mouse germ cells is enhanced by in vivo glutathione depletion: a fl ow cytometric approach. Mutat Res 1998;397:37-43.
83. Pagano G, Degan P, De Biase A. Diepoxybutane and mitomycin C toxicity is associated with the induction of oxidative DNA damage in sea urchin embryos. Hum Exp Toxicol 2001;20:651-5.
84. Reuter TY, Medhurst AL, Waisfisz Q, et al. Yeast two-hybrid screens imply involvement of Fanconi anemia proteins in transcription regulation, cell signaling, oxidative metabolism, and cellular transport. Exp Cell Res 2003;289:211-21.
85. Rani R, Li J, Pang Q. Differential p53 engagement in response to oxidative and oncogenic stresses in Fanconi anemia mice. Cancer Res 2008;68:9693-702.
86. Du W, Adam Z, Rani R, Zhang X, Pang Q. Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antioxid Redox Signal 2008;10:1909-21.
87. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38.
88. Wong AL, Lee SC. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer 2012;2012:415170.
89. Chen CC, Kennedy RD, Sidi S, et al. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009;8:24.
90. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007;11:175-89.
91. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007;13:1955-60.
92. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004;4:216-25.
93. Lara PN Jr, Mack PC, Synold T, et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 2005;11:4444-50.
94. Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005;23:1875-84.
95. Hotte SJ, Oza A, Winquist EW, et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 2006;17:334-40.
96. Sampath D, Cortes J, Estrov Z, et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006;107:2517-24.
97. Gallmeier E, Calhoun ES, Rago C, et al. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 2006;130:2145-54.
98. Gallmeier E, Kern SE. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. Clin Cancer Res 2007;13:4-10.
99. Chirnomas D, Taniguchi T, de la Vega M, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006;5:952-61.
100. Landais I, Sobeck A, Stone S. A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway. Int J Cancer 2009;124:783-92.
101. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
102. Evers B, Helleday T, Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci 2010;31:372-80.
103. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555-61.
104. D'Andrea AD. Targeting DNA repair pathways in AML. Best Pract Res Clin Haematol 2010;23:469-73.
105. Joenje H. Metabolism: alcohol, DNA and disease. Nature 2011;475:45-6.
106. Tolar J, Adair JE, Antoniou M, et al. Stem cell gene therapy for Fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting. Mol Ther 2011;19:1193-8.